Startup Dossier
Crossject
CROSSJECT is a specialty pharmaceutical company developing emergency medicines using its proprietary ZENEO® needle-free auto-injector platform. Its lead product, ZEPIZURE®, is an injectable rescue therapy for epileptic seizures currently in advanced regulatory development.
active
Typestartup
SectorBioTech
LocationDijon
About
CROSSJECT is a specialty pharmaceutical company developing emergency medicines using its proprietary ZENEO® needle-free auto-injector platform. Its lead product, ZEPIZURE®, is an injectable rescue therapy for epileptic seizures currently in advanced regulatory development.
Structural DNA
Legal Name
Crossject
SIREN
438822215
Founders & Team
Funding Lineage
Growth
0 investors
€15.0M
May 2026